Clinical

Videos

“Our preclinical therapy models all show us that the combination of the 2 agents [alpha and beta particles] is substantially superior to either agent alone,” says Neil H. Bander, MD.

Dr. Bander on PSMA breakthroughs in prostate cancer

“There's a hope that we can modulate PSMA expression with some drugs, increase the amount of PSMA on the tumors, [and] therefore increase the amount of radiation that we can target,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.

Current clinical trials examining LuPSMA

“It's very clear that PSMA-PET imaging is having…a transformative impact on our ability to image metastatic disease, in that it is much more sensitive than we've had for the last 50 plus years—and also, 98% specific,” says Neil H. Bander, MD.

Dr. Bander gives an overview of PSMA-PET imaging innovations

“We hope to further investigate next-generation PSMA-targeting molecules, develop new biomarkers to try to predict and monitor response to these novel therapies, optimize combinations with other treatments, and do some discovery research, including artificial intelligence [and] deep learning of our images,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.

Goals of ProsTIC's theranostics research in prostate cancer

“We expect an outcome from the FDA next year and if that's positive, we expect global, widespread availability of this as a new option for men with metastatic castration-resistant prostate cancer,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.

Dr. Hofman on the potential of LuPSMA in advanced prostate cancer

Articles

The SECURE trial is exploring the PSMA PET imaging product 64Cu-SAR-bisPSMA and the PSMA targeted therapy 67Cu-SAR-bisPSMA.

Trial of novel copper-based PSMA theranostics for mCRPC hits early enrollment goal

The oncology provider will enable patient access to the PSMA-PET imaging agent piflufolastat F 18, which the FDA approved in May 2021 for identifying suspected metastasis or recurrence of prostate cancer. 

PSMA-PET imaging to be available at all US GenesisCare Centers

"Combining mpMRI and 68Ga-PSMA PET/CT in a primary diagnostic setting could better identify where to target on biopsy, increasing the diagnostic yield, improving concordance with underlying tumor grade and therefore improving management recommendations," the authors wrote.

Adding PSMA PET/CT imaging to mpMRI improves detection of significant prostate cancer

In the majority of patients, the study findings resulted in impactful changes to clinical management. 

High-sensitivity total-body 18F-fluciclovine PET/CT scans show promise in prostate cancer

The nomogram was significantly prognostic of key clinical end points and achieved outcomes comparable to STAR-CAP and superior to other established risk-stratification tools. 

Next-Generation Imaging